{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:08:28Z","timestamp":1785434908004,"version":"3.56.0"},"reference-count":69,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T00:00:00Z","timestamp":1670630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005375","name":"Latvian Council of Science","doi-asserted-by":"publisher","award":["lzp-2019\/1-0380"],"award-info":[{"award-number":["lzp-2019\/1-0380"]}],"id":[{"id":"10.13039\/501100005375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>(1) Background: The safety of medicines has been receiving increased attention to ensure that the risks of taking medicines do not outweigh the benefits. This is the reason why, over several decades, the pharmacovigilance system has been developed. The post-authorization pharmacovigilance system is based on reports from healthcare professionals and patients on observed adverse reactions. The reports are collected in databases and progressively evaluated. However, there are emerging concerns about the effectiveness of the established passive pharmacovigilance system in accelerating circumstances, such as the COVID-19 pandemic, when billions of doses of new vaccines were administered without a long history of use. Currently, health professionals receive fragmented new information on the safety of medicines from competent authorities after a lengthy evaluation process. Simultaneously, in the context of accelerated mass vaccination, health professionals need to have access to operational information\u2014at least on organ systems at higher risk. Therefore, the aim of this study was to perform a primary data analysis of publicly available data on suspected COVID-19 vaccine-related adverse reactions in Europe, in order to identify the predominant groups of reported medical conditions after vaccination and their association with vaccine groups, as well as to evaluate the data accessibility on specific syndromes. (2) Methods: To achieve the objectives, the data publicly available in the EudraVigilance European Database for Suspected Adverse Drug Reaction Reports were analyzed. The following tasks were defined to: (1) Identify the predominant groups of medical conditions mentioned in adverse reaction reports; (2) determine the relative frequency of reports within vaccine groups; (3) assess the feasibility of obtaining information on a possibly associated syndrome\u2014myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS). (3) Results: The data obtained demonstrate that the predominant medical conditions induced after vaccination are relevant to the following categories: (1) \u201cGeneral disorders and administration site conditions\u201d, (2) \u201cnervous system disorders\u201d, and (3) \u201cmusculoskeletal and connective tissue disorders\u201d. There are more reports for mRNA vaccines, but the relative frequency of reports per dose administered, is lower for this group of vaccines. Information on ME\/CFS was not available, but reports of \u201cchronic fatigue syndrome\u201d are included in the database and accessible for primary analysis. (4) Conclusions: The information obtained on the predominantly reported medical conditions and the relevant vaccine groups may be useful for health professionals, patients, researchers, and medicine manufacturers. Policymakers could benefit from reflecting on the design of an active pharmacovigilance model, making full use of modern information technologies, including big data analysis of social media and networks for the detection of primary signals and building an early warning system.<\/jats:p>","DOI":"10.3390\/vaccines10122115","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T03:02:37Z","timestamp":1670814157000},"page":"2115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Vaccine Vigilance System: Considerations on the Effectiveness of Vigilance Data Use in COVID-19 Vaccination"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4558-0980","authenticated-orcid":false,"given":"Diana","family":"Araja","sequence":"first","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University, 5 Ratsupites Str., LV-1067 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0594-1091","authenticated-orcid":false,"given":"Angelika","family":"Krumina","sequence":"additional","affiliation":[{"name":"Department of Infectology, Riga Stradins University, 3 Linezera Str., LV-1006 Riga, Latvia"},{"name":"Latvian Centre of Infectious Diseases, Riga East University Hospital, 3 Linezera Str., LV-1006 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiga","family":"Nora-Krukle","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University, 5 Ratsupites Str., LV-1067 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uldis","family":"Berkis","sequence":"additional","affiliation":[{"name":"Development and Project Department, Riga Stradins University, 16 Dzirciema Str., LV-1007 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0971-1784","authenticated-orcid":false,"given":"Modra","family":"Murovska","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Virology, Riga Stradins University, 5 Ratsupites Str., LV-1067 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/pds.3305","article-title":"Evaluation of the effectiveness of risk minimization measures","volume":"21","author":"Prieto","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_2","unstructured":"Uppsala Monitoring Centre (2022, August 15). VigiBase Services. Available online: https:\/\/who-umc.org\/vigibase\/vigibase-services\/."},{"key":"ref_3","unstructured":"U.S. Food and Drug Administration (FDA) (2022, August 15). VAERS Overview, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccine-adverse-events\/vaers-overview."},{"key":"ref_4","unstructured":"European Parliament and Council of the European Union (2022, August 12). Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use. OJ L 311, 28.11.2001. Available online: https:\/\/eur-lex.europa.eu\/legal-content\/EN\/ALL\/?uri=CELEX:32001L0083."},{"key":"ref_5","unstructured":"European Medicines Agency (2022, August 14). Human Regulatory. Pharmacovigilance: Overview. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/pharmacovigilance-overview."},{"key":"ref_6","unstructured":"European Medicines Agency (2022, August 16). EudraVigilance. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","article-title":"EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection","volume":"41","author":"Postigo","year":"2018","journal-title":"Drug Saf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40264-017-0572-8","article-title":"Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works","volume":"40","author":"Santoro","year":"2017","journal-title":"Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: A mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tobaiqy, M., Elkout, H., and MacLure, K. (2021). Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines, 9.","DOI":"10.1101\/2021.03.19.21253980"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/pds.5196","article-title":"Prediction of post-vaccination Guillain-Barr\u00e9 syndrome using data from a passive surveillance system","volume":"30","author":"Luo","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102685","DOI":"10.1016\/j.jaut.2021.102685","article-title":"Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data","volume":"122","author":"Cari","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Palladino, R., Ceriotti, D., De Ambrosi, D., De Vito, M., Farsoni, M., Seminara, G., and Barone-Adesi, F. (2021). A Quantitative Benefit-Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy. Vaccines, 9.","DOI":"10.1101\/2021.05.07.21256826"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.thromres.2021.05.010","article-title":"Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination","volume":"203","author":"Douxfils","year":"2021","journal-title":"Thromb. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1080\/21645515.2021.1917236","article-title":"Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): New insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility","volume":"17","author":"Gringeri","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/jth.15493","article-title":"Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites","volume":"19","author":"Abbattista","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1111\/ene.15029","article-title":"Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: An analysis of cases notified to the European Medicines Agency","volume":"28","author":"Krzywicka","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tobaiqy, M., MacLure, K., Elkout, H., and Stewart, D. (2021). Thrombotic Adverse Events Reported for Moderna, Pfizer and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database. Vaccines, 9.","DOI":"10.1101\/2021.09.12.21263462"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.jaut.2021.102742","article-title":"Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data","volume":"125","author":"Cari","year":"2021","journal-title":"J. Autoimmun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccines"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/ene.15113","article-title":"Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination","volume":"29","author":"Krzywicka","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40264-021-01138-z","article-title":"Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity","volume":"45","author":"Ferner","year":"2022","journal-title":"Drug Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"756633","DOI":"10.3389\/fpubh.2021.756633","article-title":"Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States","volume":"9","author":"Montano","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e759","DOI":"10.1212\/WNL.0000000000013148","article-title":"Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination","volume":"98","author":"Krzywicka","year":"2022","journal-title":"Neurology"},{"key":"ref_25","first-page":"e23380","article-title":"Time-Dependent Changes in Death Reports and the Sex Ratio in the Safety Surveillance of SARS-CoV-2 Vaccination in Japan, the United States, and European Countries","volume":"14","author":"Yamashita","year":"2022","journal-title":"Cureus"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"di Mauro, G., Mascolo, A., Longo, M., Maiorino, M.I., Scappaticcio, L., Bellastella, G., Esposito, K., and Capuano, A. (2022). European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events. Pharmaceuticals, 15.","DOI":"10.3390\/ph15060677"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e059223","DOI":"10.1136\/bmjopen-2021-059223","article-title":"Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: A systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature","volume":"12","author":"Lane","year":"2022","journal-title":"BMJ Open"},{"key":"ref_28","first-page":"443","article-title":"Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management","volume":"36","author":"Luxi","year":"2022","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e060425","DOI":"10.1136\/bmjopen-2021-060425","article-title":"Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination","volume":"12","author":"Lane","year":"2022","journal-title":"BMJ Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"967926","DOI":"10.3389\/fcvm.2022.967926","article-title":"Thrombotic events with or without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines","volume":"9","author":"Cari","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"956825","DOI":"10.3389\/fimmu.2022.956825","article-title":"Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance","volume":"13","author":"Ruggiero","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s12020-022-03101-z","article-title":"Subacute thyroiditis and COVID-19 vaccines: A case\/non-case study","volume":"77","author":"Lertxundi","year":"2022","journal-title":"Endocrine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"965171","DOI":"10.3389\/fimmu.2022.965171","article-title":"Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study","volume":"13","author":"Mascolo","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Ferreras, A., Maray, I., Coya-Fern\u00e1ndez, C., Octavio-Bocigas, M.M., Fern\u00e1ndez-Del R\u00edo, M.F., Casares-L\u00f3pez, S., and Ruiz-Salazar, J. (2022). Kikuchi-Fujimoto Disease and COVID-19 vaccination: Pharmacovigilance approach. Eur. Ann. Allergy Clin. Immunol., ahead of print.","DOI":"10.23822\/EurAnnACI.1764-1489.273"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1080\/14760584.2022.2100765","article-title":"Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States","volume":"21","author":"Hatziantoniou","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Oosterhuis, I., Scholl, J., van Puijenbroek, E., Kant, A., and van Hunsel, F. (2022). Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience. Drug Saf., 1\u201311.","DOI":"10.1007\/s40264-022-01253-5"},{"key":"ref_37","unstructured":"European Medicines Agency Guidelines on Good Pharmacovigilance Practices (GVP) Module VI Collection, Management and Submission of Reports of Suspected Ad-verse Reactions to Medicinal Products (Rev 2)."},{"key":"ref_38","unstructured":"(2022, September 17). Medical Dictionary for Regulatory Activities (MedDRA), Available online: https:\/\/www.meddra.org\/."},{"key":"ref_39","unstructured":"Medical Dictionary for Regulatory Activities (2022, September 18). MedDRA Browser, Available online: https:\/\/tools.meddra.org\/wbb\/."},{"key":"ref_40","unstructured":"Global Change Data Lab. (2022, September 17). Our World in Data. Organization. Available online: https:\/\/ourworldindata.org\/organization."},{"key":"ref_41","unstructured":"European Medicines Agency (2022, September 16). EMA\u2019s EudraVigilance Access Policy. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/access-eudravigilance-data."},{"key":"ref_42","unstructured":"European Medicines Agency (2022, September 17). European Database for Suspected Adverse Drug Reaction reports. Available online: https:\/\/www.adrreports.eu\/."},{"key":"ref_43","unstructured":"Global Change Data Lab. (2022, September 17). Our World in Data. COVID-19 Vaccination. Available online: https:\/\/ourworldindata.org\/covid-vaccinations."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Araja, D., Berkis, U., Lunga, A., and Murovska, M. (2021). Shadow Burden of Undiagnosed Myalgic Encephalomyelitis\/Chronic Fatigue Syndrome (ME\/CFS) on Society: Retrospective and Prospective\u2014In Light of COVID-19. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143017"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Brenna, E., Araja, D., and Pheby, D.F.H. (2021). Comparative Survey of People with ME\/CFS in Italy, Latvia, and the UK: A Report on Behalf of the Socioeconomics Working Group of the European ME\/CFS Research Network (EUROMENE). Medicina, 57.","DOI":"10.3390\/medicina57030300"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s13365-021-01002-x","article-title":"Chronic fatigue syndrome: An emerging sequela in COVID-19 survivors?","volume":"27","author":"Mantovani","year":"2021","journal-title":"J. Neurovirol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.molmed.2021.06.002","article-title":"Insights from ME\/CFS may help unravel the pathogenesis of post-acute COVID-19 syndrome","volume":"27","author":"Komaroff","year":"2021","journal-title":"Trends Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"606824","DOI":"10.3389\/fmed.2020.606824","article-title":"Will COVID-19 lead to myalgic encephalomyelitis\/chronic fatigue syndrome?","volume":"7","author":"Komaroff","year":"2021","journal-title":"Front. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1038\/s41467-022-32507-6","article-title":"A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity","volume":"13","author":"Kedor","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Loosen, S.H., Bohlken, J., Weber, K., Konrad, M., Luedde, T., Roderburg, C., and Kostev, K. (2022). Factors Associated with Non-Severe Adverse Reactions after Vaccination against SARS-CoV-2: A Cohort Study of 908,869 Outpatient Vaccinations in Germany. Vaccines, 10.","DOI":"10.3390\/vaccines10040566"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/neurolint13040061","article-title":"Spectrum of Neuroimaging Findings in Post-COVID-19 Vaccination: A Case Series and Review of Literature","volume":"13","author":"Sriwastava","year":"2021","journal-title":"Neurol. Int."},{"key":"ref_52","first-page":"1663","article-title":"COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfiz-er\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Sin-gle-Dose Ad26.COV2.S Vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"108786","DOI":"10.1016\/j.clim.2021.108786","article-title":"Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study","volume":"229","year":"2021","journal-title":"Clin. Immun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(98)23016-9","article-title":"Adverse drug reactions remain a major cause of death","volume":"351","author":"Bonn","year":"1998","journal-title":"Lancet"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Hacker, M. (2009). Chapter 13\u2014Adverse Drug Reactions. Book Pharmacology. Principles and Practice, Academic Press.","DOI":"10.1016\/B978-0-12-369521-5.00013-0"},{"key":"ref_59","unstructured":"European Commission (2022, September 08). Strengthening Pharmacovigilance to Reduce Adverse Effects of Medicines. Available online: https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/de\/MEMO_08_782."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cpt.1678","article-title":"Improving the Safety of Medicines in the European Union: From Signals to Action","volume":"107","author":"Potts","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_61","unstructured":"U.S. Food and Drug Administration (2022, September 08). COVID-19 Vaccine Safety Surveillance, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/covid-19-vaccine-safety-surveillance."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"102898","DOI":"10.1016\/j.jaut.2022.102898","article-title":"Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review","volume":"132","author":"Rojas","year":"2022","journal-title":"J. Autoimmun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/imm.13443","article-title":"New-onset autoimmune phenomena post-COVID-19 vaccination","volume":"165","author":"Chen","year":"2022","journal-title":"Immunology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10067-022-06149-4","article-title":"Au-toimmune post-COVID vaccine syndromes: Does the spectrum of autoim-mune\/inflammatory syndrome expand?","volume":"41","author":"Jara","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/1756-185X.14238","article-title":"COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells","volume":"25","author":"Sachinidis","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"109061","DOI":"10.1016\/j.intimp.2022.109061","article-title":"Autoimmune inflammatory rheumatic diseases post-COVID-19 vaccination","volume":"110","author":"Safary","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Araja, D., Berkis, U., and Murovska, M. (2022). COVID-19 Pandemic-Revealed Consistencies and Inconsistencies in Healthcare: A Medical and Organizational View. Healthcare, 10.","DOI":"10.3390\/healthcare10061018"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jbi.2015.01.011","article-title":"Filtering big data from social media \u2013 Building an early warning system for adverse drug reactions","volume":"54","author":"Yang","year":"2015","journal-title":"J. Biomed. Inform."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1108\/OIR-10-2015-0341","article-title":"Adverse drug reaction early warning using user search data","volume":"41","author":"Shang","year":"2017","journal-title":"Online Inf. Rev."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:37:46Z","timestamp":1760146666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/12\/2115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,10]]},"references-count":69,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["vaccines10122115"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10122115","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,10]]}}}